Local molecular tumour profile showed 91 (49%) RAS mutant tumours, 8 (4%) BRAF V600E tumours and 6 (3%) MSI‐H/dMMR tumours, although MMR status was not fully completed in the whole cohort. The gene discussed is BRAF; the disease is neoplasm.